Yahoo Finance

Announcing Marketing Approval for Hunterase ICV Injection 15 mg, the World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) Administered ...

GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, and Clinigen K.K. ("Clinigen"), headquartered in Tokyo, has received on January 22, 2021, ...
Business Wire

GC Pharma Announces EMA Grants Orphan Drug Designation to Hunterase ICV, The World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II Administered by ICV ...

YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (006280.KS) today announced that the European Medicines Agency (EMA) granted orphan drug designation (ODD) to Hunterase ICV (intracerebroventricular, ...
Pharmabiz

CANbridge, UMass Chan Medical School SMA gene therapy, CAN203 improves lifespan and motor function in mice when administered via intracerebroventricular injection

CANbridge Pharmaceuticals Inc., a leading China-based global biopharmaceutical company, announced that data on a novel second-generation spinal muscular atrophy (SMA) gene therapy (CAN203), developed ...